News & Updates

New drug applications approved by US FDA as of 1-15 July 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

The use of intravenous (IV) buprenorphine appears to be a good substitute for full agonist IV opioids for managing pain in the medical intensive care unit (ICU), suggests a study.

Pregnant women who are using lithium are at increased risk of spontaneous preterm birth, according to a retrospective study.

The number of infants not receiving intramuscular vitamin K to prevent bleeding episodes is increasing, and this translates to an increased risk of bleeding episodes, including intracranial haemorrhages, according to a nationwide cohort study from Sweden.

Treatment with carvedilol, compared with nadolol or propranolol, results in reduced rates of major decompensation events among patients with cirrhosis, a study has shown.

In patients with obesity but without diabetes, treatment with survodutide results in substantial reductions in body weight compared with placebo, according to the phase III SYNCHRONIZE-1 trial.

Treatment with oral venglustat demonstrates superior neurologic outcomes compared with standard enzyme replacement therapy (ERT) in patients with Gaucher disease type 3 (GD3), according to the phase III LEAP2MONO trial presented at EHA 2026.

Treatment with lemborexant helps manage sleep disturbances in patients with liver cirrhosis, as shown in the crossover RESTORE trial.

The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) results in an increased risk for ischaemic optic neuropathy (ION) at 18 months when compared with the use of sodium‒glucose cotransporter-2 inhibitors (SGLT2is) and dipeptidyl peptidase-4 inhibitors (DPP4is), reports a study.